Biased Ligands. Better Drugs.

Press Releases

6/16/16 - Trevena to Present at the JMP Life Sciences Conference

Trevena, Inc. today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m. EDT in New York. Read More

6/8/16 - Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain

Trevena, Inc. today announced the enrollment of the first patients in the Phase 3 APOLLO-1 and APOLLO-2 studies of oliceridine in patients suffering moderate to severe acute pain following bunionectomy and abdominoplasty, respectively.

Read More

6/1/16 - Trevena to Present at the Jefferies 2016 Healthcare Conference

Trevena, Inc. today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m. EDT in New York.

Read More

5/16/16 - Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
Trevena, Inc. today announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). Read More

5/11/16 - Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society
Trevena, Inc. (NASDAQ: TRVN), today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. Read More

5/5/16 - Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update
Trevena, Inc. today announced financial results for the quarter ended March 31, 2016 and provided an update regarding its ongoing clinical programs. Read More

5/2/16 - Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
Trevena, Inc. today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA). The company has reached general agreement with the FDA on key elements of the Phase 3 program to support a New Drug Application (NDA) for oliceridine (TRV130), to which the FDA has granted Breakthrough Therapy designation. Read More

4/15/16 - Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
Trevena, Inc. today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Read More

4/7/16 - Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
Trevena, Inc. today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York. Read More

3/31/16 - Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
Trevena, Inc. today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting. The poster presentations highlight data from the oliceridine program, including key data from the Company’s Phase 2b trial in acute pain following abdominoplasty. Read More

3/9/16 - Trevena Reports Full Year 2015 Financial Results

Trevena, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update regarding its ongoing clinical programs.

Read More

3/3/16 - Trevena to Present at Three Upcoming Investor Events in March
Trevena, Inc. today announced that the company will be presenting at the Cowen 36th Annual Health Care Conference in Boston, the 28th Annual ROTH Conference in Orange County, and the Barclays Global Healthcare Conference in Miami. Read More

3/2/16 - Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results
Trevena, Inc. today announced that it will host a conference call on Wednesday, March 9, 2016 at 7:30 a.m. Eastern Time to discuss financial results as of and for the year ended December 31, 2015, as well as 2015 and recent corporate highlights. Read More

2/22/16 - Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine
Trevena, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the Company's lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain. Read More

2/17/16 - Trevena to present at the 2016 RBC Capital Markets' Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that David Soergel, M.D., its chief medical officer, will present a company overview and update at the 2016 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 23, 2016 at 2:05 p.m. EST in New York. Read More

2/3/16 - Trevena to present at the 18th Annual BIO CEO & Investor Conference
Trevena, Inc. today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York. Read More

1/19/16 - Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program
Trevena, Inc., today announced the launch of the oliceridine (TRV130) Phase 3 clinical program with the enrollment of patients in the open label Phase 3 ATHENA-1 study. Read More

Copyright © Trevena, Inc.